No abstract available.
Fibromyalgia*

No abstract available.
Fibromyalgia*

No abstract available.
Fatigue Syndrome, Chronic* ; Fibromyalgia

Background: Fibromyalgia is a difficult-to-treat chronic musculoskeletal pain and tenderness syndrome. It is considered due to augmented pain processing in central nervous system. Interest in antiepileptic drugs, included pregabalin, for treatment of fibromyalgia is currently growing. This study aimed to investigate the effectiveness of pregabalin for fibromyalgia. Methods: We conducted the study according to the meta-analysis PRISMA guideline. Relevant randomized controlled trials (RCTs) were identified from a search of PubMed and Cochrane databases. Quality of selected studies was assessed using Jadad score for randomized placebo-controlled trials (RCT). Primary outcome was pain score reduction (30% and 50% reduction) and secondary outcome was patient global impression of change. Statistical analysis was performed using Review Manager 5.3. Results: Six international, multicenter, high-quality RCTs with 8-15 weeks duration of treatment met inclusion criteria. Four studies used different fixed dose (300 mg/d, 450 mg/d, 600mg/d) and 2 studies used titrated dose in evaluating the efficacy of pregabalin. There was statistically significant benefit of pregabalin over placebo in mean pain score reduction [odds ratio (OR) 1.81, 95% confidence interval (CI) 1.56-2.10 p < 0.00001 in fixed dose pregabalin 30% pain reduction; OR 2.06 95% CI 1.66-2.56 p < 0.00001 in fixed dose pregabalin 50% pain reduction; OR 1.53 95% CI 1.10-2.13 p 0.01 in titrated dose pregabalin 30% pain reduction; OR 1.80 95% CI 1.12-2.88 p 0.01 in titrated dose pregabalin 50% pain reduction]. Pregabalin also demonstrated significantly better patient global impression of change than placebo. No heterogeneity was seen in most groups. No publication bias was observed. Conclusion Our study showed pregabalin monotherapy was effective for pain treatment associated with fibromyalgia. Further studies with longer treatment duration are needed to confirm the long-term effectiveness of pregabalin for fibromyalgia treatment.
Fibromyalgia ; Pregabalin ; Meta-Analysis

BACKGROUND: Dry eye is a disorder of the tear film caused by reduced tear production or excessive tear evaporation. A high incidence of sicca symptoms has been noted in fibromyalgia (FM) patients resulting in serious complications. This study was conducted to evaluate the incidence of dry eye by pathogenic mechanisms and to investigate the relationship between dry eye and symptom severity in FM patients. METHODS: Fifty patients that visited Maryknoll Hospital between March 2006 and December 2006 were included in the study. Enrolled patients underwent a Korean fibromyalgia impact questionnaire (KFIQ), ocular surface disease index (OSDI), Schirmer test and tear break up test (TBUT). The KFIQ and OSDI are used to assess the severity of fibromyalgia symptoms and dry eye symptoms, respectively. The Schirmer test and TBUT are used to assess reduced tear production and excessive tear evaporation, respectively. We assessed the OSDI, Schirmer test, TBUT, age and disease duration in terms of the KFIQ. RESULTS: The incidence of dry eye was high in FM patients (12.0% by the Schirmer test and 92.0% by the TBUT test). The OSDI positively correlated with the KFIQ (p=0.006). A positive correlation was observed between the Schirmer test and the KFIQ (p=0.024), but not between the TBUT and the KFIQ. CONCLUSIONS: In this study, dry eye was found to be common in FM patients. Excessive tear evaporation was a more common cause of dry eye than reduced tear production. The patients with more severe dry eye symptoms tend to have more severe FM symptoms.
Fibromyalgia* ; Humans ; Incidence ; Tears ; Surveys and Questionnaires

We report on a case of severe generalized pain due to fibromyalgia syndrome, which was successfully treated with a variation of byakkoto. A 65-year-old Japanese woman had severe generalized pain which grew worse in warm environments, such as during the summer or when bathing. She also had pollakidipsia. We utilized a variation of byakkoto on the assumption that she was suffered from high inner heat. Her severe generalized pain resolved with this therapy. Although bushi-zai and saiko-zai are common prescriptions for fibromyalgia syndrome, byakkoto-variations may also be effective in cases where conditions are worsened by heat effect.
Fibromyalgia ; Pain ; Treated with ; Generalized aches and pains ; Syndrome

BACKGROUND: Fibromyalgia (FM) is characterized by chronic widespread pain with a low pain threshold. The aim of this study was to compare two criteria for the diagnosis and assessment of FM and to analyze the correlation and agreement between the 1990 and 2010 American College of Rheumatology (ACR) preliminary diagnostic criteria for FM. METHODS: We studied 98 patients who had already been diagnosed as having FM using the 1990 criteria or 2010 preliminary criteria. Tender point examination, FM impact questionnaire (FIQ) and pain visual analog scale (VAS) were obtained. According to the preliminary criteria, FM was quantified as WPI (widespread pain index) and the SS scale (symptom severity) and the two criteria were compared. RESULTS: Among 98 patients, 78.6% of the patients were diagnosed with the 1990 ACR criteria and 93.9% of the patients were diagnosed with the ACR preliminary diagnostic criteria, and there was also significant agreement between the two criteria (P < 0.01). There was a correlation with the WPI and the tender point, with the SS and the FIQ, and with the sum of the WPI and SS and the FIQ. CONCLUSIONS: The ACR preliminary diagnostic criteria for FM were in agreement with the 1990 ACR criteria during the disease course. The preliminary criteria were the more sensitive method than the 1990 criteria. In addition, the 2010 criteria might have advantages since it is easy to assess the physical and psychological symptoms and can be quantified. Therefore, the ACR preliminary diagnostic criteria for FM could be used more conveniently for clinical diagnosis and follow up evaluation after starting management of FM.
Fibromyalgia ; Follow-Up Studies ; Humans ; Pain Threshold ; Surveys and Questionnaires ; Rheumatology

No abstract available.
Fibromyalgia* ; Humans ; Physicians, Primary Care* ; Primary Health Care*

OBJECTIVE: To investigate soluble Fas (sFas) protein in the sera of patients with systemic lupus erythematosus (SLE). METHODS: sfas protein was measured by sandwich ELISA METHOD: in the sera of 30 patients with SLE (mean age : 27.4+/-8.46, F:M=29:1) and 11 patients with fibromyalgia (mean age 35.8+/-11.5, F:M-11:0) as a control group. RESULTS: sfas was elevated in 6 (20%) patients of SLE and I (9%) of patients with fibromyalgia (p=0.41). sfas level was correlated with a shorter duration, lower dosage of systemic steroid and higher disease activity in patients with elevated sfas levlel compared to patients with normal serum levels of sfas. All patients with elevated sfas had been diagnosed with SLE for less than 1 month. Fifty % (6 out of 12)patients with SLE for less than I month showed elevated sfas in serum. There was no difference of in the age between patients with elevated and normal levels of sfas. CONCLUSION: These data indicate that elevated sera levels of sfas was associated with the early active phase of disease in some patients with SLE and may play a role in defective apoptosis.
Apoptosis ; Enzyme-Linked Immunosorbent Assay ; Fibromyalgia ; Humans ; Lupus Erythematosus, Systemic*

Since Smythe and Moldofsky proposed the first modern definition of fibromyalgia (FM), a number of different classification and diagnostic criteria have emerged. Among these criteria, the 1990 American College of Rheumatology (ACR) classification criteria have been the most widely accepted in both research and clinical settings. The 1990 ACR criteria were originally established as inclusion criteria for research purposes and were not intended for clinical diagnosis, but have become the de facto diagnostic criteria in clinical settings. However, an improved clinical case definition for FM, using diagnostic criteria that can be used by both primary care physicians and specialists has been desired for a long time. For this, Wolfe and colleagues developed several sets of diagnostic criteria and their last one received the endorsement of ACR, which is now known as the 2010 ACR diagnostic criteria. Unfortunately, the new criteria have been criticized as being inconsistent, non-specific, and lacking the ability to recognize FM concurrent with other diseases. Further studies are needed to assess the acceptance, reliability, and validity of the new criteria in epidemiologic and clinical studies.
Fibromyalgia ; Humans ; Physicians, Primary Care ; Rheumatology ; Specialization ; Wolves